Filed by Flex Pharma, Inc.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule
under the Securities Exchange Act of 1934
Subject Company: Salarius Pharmaceuticals, LLC
SEC File No.:
Flex Pharma, Inc. intends to send the following press release to its stockholders.
Flex Pharma Announces Overwhelming Support to Date for the Proposed Merger with
Salarius Pharmaceuticals but More Votes are Needed to Complete the Merger
Special Meeting of Stockholders Adjourned Until July
BOSTON June 17, 2019
Flex Pharma, Inc.
(Nasdaq: FLKS) today announced that approximately 85% of shares voted to date support the
proposed merger with Salarius Pharmaceuticals, LLC, an epigenetic oncology company. However, in order to complete the merger, a quorum must be present at the special meeting (in person or by proxy) and a majority of outstanding shares must approve
Proposal 2, which is described in Flex Pharmas proxy statement/prospectus/information statement.
Flex Pharma adjourned the special meeting until
July 12, 2019 in order to provide shareholders with more time to complete proxies and vote their shares.
Flex Pharmas CEO William McVicar
stated, We are very pleased that the vast majority of shareholders who voted support the merger with Salarius, consistent with the recommendations of both leading, independent proxy advisory services ISS and Glass-Lewis. Flex
Pharmas Board of Directors also unanimously recommends voting FOR all proposals in the proxy statement/prospectus/information statement as the best way to preserve future shareholder value.
Additional shares must be voted in order to complete the planned merger with Salarius Pharmaceuticals, LLC, a privately held clinical-stage oncology company
targeting the epigenetic causes of cancers.
ADDITIONAL VOTES ARE REQUIRED TO COMPLETE THE MERGER
- URGENT ACTION NEEDED BEFORE July 12, 2019 -
All shareholders are urged to vote
as soon as possible
FOR all proposals in the proxy statement/prospectus/information statement by
telephone, via the Internet or using the proxy card they received with their proxy materials. For any questions, or assistance in voting shares, or to receive additional copies of the proxy materials, shareholders should call Flex Pharmas
proxy solicitor, Innisfree M&A Incorporated, toll-free at 1 (888)
Your vote is important. If Flex
Pharma does not complete the merger, it likely
will wind-up, which
could cause shareholders to lose most of the value of their investment